腎上腺皮質激素抑制劑市場規模、佔有率和成長分析：按藥物類型、適應症、分銷管道和地區分類 - 產業預測，2026-2033年

2024 年全球皮質類固醇市場價值為 7.82 億美元，預計將從 2025 年的 8.43 億美元成長到 2033 年的 15.3737 億美元，在預測期（2026-2033 年）內以 7.8% 的複合年成長率成長。

全球皮質類固醇抑制劑市場的主要驅動力是長期使用糖皮質激素導致醫源性庫欣氏症發病率的上升，從而導致需要降低皮質醇水平藥物的患者群體不斷擴大。這種需求的成長促使健康保險公司和醫療機構採用已通過核准的抑制劑。例如，奧西洛司他（osilodrostat）近期被納入國家藥品目錄，導致處方箋顯著增加。此外，包含mTOR拮抗劑的聯合治療的開發正在拓展治療適應症範圍和市場機會。生物相似藥的開發和數位化用藥依從性支援工具的進步也有望加速市場滲透，同時有效降低醫療系統的實施成本。人工智慧在加速抑制劑發現、提高研究效率和促進生物技術領域的合作方面也發揮著至關重要的作用。

全球皮質類固醇抑制劑市場促進因素

全球糖皮質激素抑制劑市場的主要促進因素是自體免疫疾病和發炎性疾病的日益流行，這顯著增加了對有效治療方法的需求。隨著醫療專業人員致力於更有效地管理類風濕性關節炎、狼瘡和氣喘等疾病，對能夠調節腎上腺激素分泌的糖皮質激素抑制劑的需求不斷成長，它們被視為一種很有前景的治療選擇。此外，人們對長期使用糖皮質激素相關副作用的認知不斷提高，推動了更安全、更具針對性的療法的研發，進一步加速了該領域的市場成長和創新。

全球皮質類固醇市場的限制因素

影響全球糖皮質激素抑制劑市場的主要限制因素之一是嚴格的法規環境，該環境規範著藥物的批准和商業化。核准流程漫長而複雜，可能會延緩新療法的上市，並限制製造商的市場機會。此外，與糖皮質激素抑制劑相關的副作用風險引起了醫療專業人員和患者的擔憂，導致處方行為謹慎。這種謹慎態度可能導致醫生傾向於選擇成熟的療法而非新興療法，從而影響糖皮質激素抑制劑在臨床實踐中的應用，並限制市場成長。

皮質類固醇抑制劑的全球市場趨勢

全球皮質類固醇市場正經歷著向精準醫療的重大轉變，這主要得益於基因組學的進步，它最佳化了治療方案。這一轉變使醫療專業人員能夠根據獨特的分子特徵識別特定的患者亞群，從而製定出以療效為先、副作用最小化的標靶治療策略。因此，製藥公司越來越重視將基因生物標記整合到產品開發流程中，並與診斷公司建立合作關係，共同開發伴隨診斷測試。這種合作模式有助於推進個人化醫療，提高皮質類固醇療法的整體療效，並符合全球長期疾病管理的趨勢。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系圖譜
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球腎上腺皮質激素抑制劑市場規模：依藥物類型分類

• 類固醇合成抑制劑
• 糖皮質激素受體拮抗劑

全球腎上腺皮質激素市場規模：依適應症分類

• 庫欣氏症候群
• 腎上腺癌
• 高皮質醇血症
• 其他內分泌疾病

全球腎上腺皮質激素市場規模：依通路分類

• 醫院藥房
• 零售藥房
• 網路藥房

全球腎上腺皮質激素市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• HRA Pharma Rare Diseases
• Recordati SpA
• Corcept Therapeutics Incorporated
• Novartis AG
• Pfizer Inc.
• Merck KGaA
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Limited
• Lupin Limited
• AbbVie Inc.
• Bayer AG
• Boehringer Ingelheim International GmbH
• Amneal Pharmaceuticals, Inc.
• Zydus Lifesciences Limited
• Mylan NV
• Astellas Pharma Inc.
• Takeda Pharmaceutical Company Limited
• AstraZeneca PLC
• GlaxoSmithKline plc
• Sanofi SA

結論與建議

Global Adrenal Corticosteroid Inhibitors Market size was valued at USD 782.0 Million in 2024 and is poised to grow from USD 843.0 Million in 2025 to USD 1537.37 Million by 2033, growing at a CAGR of 7.8% during the forecast period (2026-2033).

The market for global adrenal corticosteroid inhibitors is primarily driven by the increasing incidence of iatrogenic Cushing's disease resulting from prolonged glucocorticoid use, thereby expanding the patient base in need of cortisol-lowering agents. This rising demand has prompted health insurers and providers to adopt approved inhibitors, such as the notable increase in prescriptions following the recent inclusion of osilodrostat in national formularies. Furthermore, the development of combination therapies that incorporate mTOR antagonists is enhancing market opportunities by broadening treatment indications. Additionally, advancements in biosimilar development and digital adherence tools are expected to facilitate market penetration while effectively lowering acquisition costs for health systems. Artificial intelligence is also playing a crucial role by accelerating the discovery of inhibitors, enhancing research efficiency, and fostering collaborations in the biotech sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Adrenal Corticosteroid Inhibitors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Adrenal Corticosteroid Inhibitors Market Segments Analysis

Global adrenal corticosteroid inhibitors market is segmented by drug type, indication, distribution channel and region. Based on drug type, the market is segmented into Steroidogenesis Inhibitors and Glucocorticoid Receptor Antagonists. Based on indication, the market is segmented into Cushing Syndrome, Adrenal Cancer, Hypercortisolism and Other Endocrine Disorders. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Adrenal Corticosteroid Inhibitors Market

A key market driver for the global adrenal corticosteroid inhibitors market is the rising prevalence of autoimmune disorders and inflammatory diseases, which has significantly increased the demand for effective treatment options. As healthcare professionals seek to manage conditions such as rheumatoid arthritis, lupus, and asthma more effectively, the need for adrenal corticosteroid inhibitors that can modulate adrenal hormone production offers promising therapeutic alternatives. Additionally, the growing awareness of the side effects associated with long-term corticosteroid use is propelling research and development efforts toward safer, more targeted therapies, further stimulating market growth and innovation in this sector.

Restraints in the Global Adrenal Corticosteroid Inhibitors Market

One of the key market restraints affecting the global adrenal corticosteroid inhibitors market is the stringent regulatory environment governing the approval and commercialization of pharmaceutical products. The lengthy and complex approval processes can delay the introduction of new therapies, limiting market opportunities for manufacturers. Additionally, the potential for adverse side effects associated with adrenal corticosteroid inhibitors raises concerns among healthcare providers and patients, leading to cautious prescribing practices. This wariness can restrict market growth as doctors may prefer established treatments over newer alternatives, thus impacting the overall adoption of adrenal corticosteroid inhibitors in clinical settings.

Market Trends of the Global Adrenal Corticosteroid Inhibitors Market

The Global Adrenal Corticosteroid Inhibitors market is experiencing a significant shift towards precision medicine, driven by advancements in genomics that refine therapy selection. This evolution allows healthcare providers to identify specific patient subpopulations based on distinct molecular characteristics, leading to targeted treatment strategies that prioritize efficacy while minimizing adverse effects. As a result, pharmaceutical companies are increasingly focused on integrating genomic biomarkers into their product development processes, fostering partnerships with diagnostic firms to create companion tests. This collaborative approach supports personalized medicine initiatives, enhancing the overall effectiveness of adrenal corticosteroid therapies and aligning with global trends in long-term disease management.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Adrenal Corticosteroid Inhibitors Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Steroidogenesis Inhibitors
• Glucocorticoid Receptor Antagonists

Global Adrenal Corticosteroid Inhibitors Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Cushing Syndrome
• Adrenal Cancer
• Hypercortisolism
• Other Endocrine Disorders

Global Adrenal Corticosteroid Inhibitors Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Adrenal Corticosteroid Inhibitors Market Size & CAGR (2026-2033)

• North America (Drug Type, Indication, Distribution Channel)
  • US
  • Canada
• Europe (Drug Type, Indication, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Indication, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Indication, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Indication, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• HRA Pharma Rare Diseases
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recordati S.p.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Corcept Therapeutics Incorporated
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amneal Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations